American Trust Increases Stake in Hologic, Inc. (NASDAQ:HOLX)

American Trust grew its stake in Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 5.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 4,864 shares of the medical equipment provider’s stock after buying an additional 238 shares during the quarter. American Trust’s holdings in Hologic were worth $314,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in HOLX. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Hologic by 5.1% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider’s stock worth $2,569,000 after purchasing an additional 1,631 shares during the last quarter. LSV Asset Management lifted its stake in Hologic by 307.5% during the first quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider’s stock worth $2,911,000 after purchasing an additional 28,600 shares during the last quarter. Raymond James Trust N.A. lifted its stake in Hologic by 7.4% during the first quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider’s stock worth $528,000 after purchasing an additional 476 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Hologic by 4.8% during the first quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock worth $177,098,000 after purchasing an additional 106,315 shares during the last quarter. Finally, Aviva PLC lifted its stake in Hologic by 0.7% during the first quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider’s stock worth $5,803,000 after purchasing an additional 513 shares during the last quarter. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Insider Activity

In related news, insider Benjamin Jordan Cohn sold 9,128 shares of the company’s stock in a transaction on Tuesday, February 7th. The stock was sold at an average price of $85.28, for a total transaction of $778,435.84. Following the transaction, the insider now owns 14,298 shares of the company’s stock, valued at $1,219,333.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.66% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HOLX shares. Citigroup boosted their target price on Hologic from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Thursday, February 2nd. Wells Fargo & Company boosted their target price on Hologic from $75.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 10th. Morgan Stanley boosted their price objective on Hologic from $74.00 to $81.00 and gave the company an “equal weight” rating in a research note on Friday, February 3rd. JPMorgan Chase & Co. boosted their price objective on Hologic from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Thursday, February 2nd. Finally, SVB Leerink boosted their price objective on Hologic from $90.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, February 2nd. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $84.08.

Hologic Trading Down 1.6 %

NASDAQ:HOLX opened at $77.07 on Friday. The firm has a market cap of $19.00 billion, a P/E ratio of 19.66, a PEG ratio of 1.40 and a beta of 1.01. The company has a current ratio of 4.21, a quick ratio of 3.50 and a debt-to-equity ratio of 0.55. The stock’s 50 day simple moving average is $81.04 and its 200-day simple moving average is $74.00. Hologic, Inc. has a 12-month low of $59.78 and a 12-month high of $86.65.

Hologic (NASDAQ:HOLX – Get Rating) last released its earnings results on Wednesday, February 1st. The medical equipment provider reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.17. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 25.12% and a net margin of 22.17%. The company’s revenue for the quarter was down 27.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.17 earnings per share. Equities analysts anticipate that Hologic, Inc. will post 3.74 EPS for the current year.

Hologic Company Profile

(Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.